{"id":"W2885455637","doi":"","title":"Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Refractory (planetary science); Randomized controlled trial; Oncology; Internal medicine; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005849581,0.00152314,0.003701155,0.0005325406,0.0005529994,0.002401227,0.001282802,0.001465734,0.004843678],"category_scores_gemma":[0.004479688,0.0005998056,0.002834533,0.000787314,0.0007473496,0.002189358,0.0005911314,0.004676106,0.001561297],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001491358,"about_ca_system_score_gemma":0.002057172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001576146,"about_ca_topic_score_gemma":0.007091186,"domain_scores_codex":[0.9984901,0.0007565068,0.0001223695,0.0001828657,0.0002134201,0.0002347543],"domain_scores_gemma":[0.9979807,0.0005251172,0.0005413632,0.0001744186,0.0002597789,0.0005187267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7744578,0.002857273,0.003654386,0.003310776,0.007807928,0.0001037514,0.0001991575,0.001834276,0.005632581,0.0005788503,0.02311606,0.1764472],"study_design_scores_gemma":[0.9390706,0.03109476,0.009506263,0.0003761212,0.005072236,0.0001738993,0.00008498281,0.0009454821,0.0009208628,0.0006733116,0.01201314,0.00006838368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8408571,0.1053338,0.002449765,0.01276401,0.002948083,0.005121228,0.01101094,0.001179475,0.01833568],"genre_scores_gemma":[0.925254,0.0337668,0.004873121,0.008989313,0.001370015,0.004340641,0.0133245,0.0002647636,0.007816757],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005849581,"threshold_uncertainty_score":0.03093594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02737241111487777,"score_gpt":0.3839136145247545,"score_spread":0.3565412034098768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}